Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Dermatologic 1

Conditions

Carcinoma, Basal Cell 3Basal Cell Nevus Syndrome 3Pancreatic Neoplasms 1Neoplasms 1Chondrosarcoma 1Bone Neoplasms 1

Interventions

belinostat 2Gemcitabine 2Fluorouracil 2venetoclax 1toripalimab 1tazemetostat 1resiquimod 1poly ICLC 1perifosine 1pazopanib 1ivosidenib 1envafolimab 1enasidenib 1durvalumab 1drozitumab 1birinapant 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Medicare Part B 1Loperamide 1Leucovorin 1Irinotecan 1Immunotherapy 1Immune Checkpoint Inhibitors 1Imatinib Mesylate 1IPI-926 1IFL protocol 1Fentanyl 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Chondrosarcoma × IPI-926 × Clear all
NCT01609179 2012-11-14

IPI-926 Extension Protocol for Continuation of Treatment With IPI-926

Infinity Pharmaceuticals, Inc.

Phase NA Completed
9 enrolled
DermatologicSarcoma

Carcinoma, Basal Cell, Chondrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡